Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.43 USD | -0.45% | -2.77% | -19.21% |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 165M | Capitalization | 1.41B |
---|---|---|---|---|---|
Net income 2024 * | -325M | Net income 2025 * | -382M | EV / Sales 2024 * | 4.24 x |
Net cash position 2024 * | 610M | Net cash position 2025 * | 270M | EV / Sales 2025 * | 6.9 x |
P/E ratio 2024 * |
-4.01
x | P/E ratio 2025 * |
-3.61
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.83% |
Latest transcript on Arcus Biosciences, Inc.
1 day | -0.45% | ||
1 week | -2.77% | ||
Current month | -18.27% | ||
1 month | -6.09% | ||
3 months | -0.06% | ||
6 months | -4.64% | ||
Current year | -19.21% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 14-12-31 |
Terry Rosen
CEO | Chief Executive Officer | 64 | 14-12-31 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 64 | 14-12-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 17-09-17 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 15-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 27 M€ | -4.43% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 15.43 | -0.45% | 523,764 |
24-04-23 | 15.5 | +5.59% | 582,461 |
24-04-22 | 14.68 | +0.62% | 450,974 |
24-04-19 | 14.59 | -1.68% | 597,302 |
24-04-18 | 14.84 | 0.00% | 913,975 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.21% | 1.41B | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- RCUS Stock